NO331655B1 - Farmasoytisk preparat i tablettform omfattende levotyroksin-natrium og fremgangsmate for fremstilling derav - Google Patents

Farmasoytisk preparat i tablettform omfattende levotyroksin-natrium og fremgangsmate for fremstilling derav Download PDF

Info

Publication number: NO331655B1
Authority: NO; Norway
Prior art keywords: sodium; levothyroxine sodium; pharmaceutical preparation; preparation; levothyroxine
Prior art date: 1998-05-15

Application number

NO20005758A

Other languages

English (en)

Norwegian (no)

Other versions

NO20005758L (no

NO20005758D0 (no

Inventor

Sven Schreder

Marion Nischwitz

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-15

Filing date

2000-11-14

Publication date

2012-02-13

2000-11-14 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2000-11-14 Publication of NO20005758L publication Critical patent/NO20005758L/no

2000-11-14 Publication of NO20005758D0 publication Critical patent/NO20005758D0/no

2012-02-13 Publication of NO331655B1 publication Critical patent/NO331655B1/no

Links

XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 title claims abstract description 26
229960003918 levothyroxine sodium Drugs 0.000 title claims abstract description 24
238000000034 method Methods 0.000 title claims abstract description 6
238000002360 preparation method Methods 0.000 title abstract description 12
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
239000000945 filler Substances 0.000 claims abstract description 11
108010010803 Gelatin Proteins 0.000 claims abstract description 9
239000008273 gelatin Substances 0.000 claims abstract description 9
229920000159 gelatin Polymers 0.000 claims abstract description 9
235000019322 gelatine Nutrition 0.000 claims abstract description 9
235000011852 gelatine desserts Nutrition 0.000 claims abstract description 9
239000003960 organic solvent Substances 0.000 claims abstract description 5
239000000825 pharmaceutical preparation Substances 0.000 claims description 18
239000000203 mixture Substances 0.000 claims description 10
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 9
239000000314 lubricant Substances 0.000 claims description 6
229920002261 Corn starch Polymers 0.000 claims description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
239000008120 corn starch Substances 0.000 claims description 5
239000008101 lactose Substances 0.000 claims description 5
229960002018 liothyronine sodium Drugs 0.000 claims description 5
SBXXSUDPJJJJLC-YDALLXLXSA-M liothyronine sodium Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 SBXXSUDPJJJJLC-YDALLXLXSA-M 0.000 claims description 5
235000019359 magnesium stearate Nutrition 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 4
229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
239000002360 explosive Substances 0.000 claims description 3
229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
239000008108 microcrystalline cellulose Substances 0.000 claims description 3
239000002245 particle Substances 0.000 claims description 3
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 2
238000005469 granulation Methods 0.000 claims 1
230000003179 granulation Effects 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
238000012360 testing method Methods 0.000 description 5
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 5
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 4
239000000725 suspension Substances 0.000 description 4
229940034208 thyroxine Drugs 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229920003091 Methocel™ Polymers 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
229950008325 levothyroxine Drugs 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
238000005422 blasting Methods 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
229960002645 boric acid Drugs 0.000 description 1
235000010338 boric acid Nutrition 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
229940078456 calcium stearate Drugs 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000004040 coloring Methods 0.000 description 1
-1 colouring Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009477 fluid bed granulation Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229910017053 inorganic salt Inorganic materials 0.000 description 1
229960003136 leucine Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229940091250 magnesium supplement Drugs 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229940056211 paraffin Drugs 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
239000011734 sodium Substances 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
229960003885 sodium benzoate Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940032147 starch Drugs 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940033134 talc Drugs 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

NO20005758A 1998-05-15 2000-11-14 Farmasoytisk preparat i tablettform omfattende levotyroksin-natrium og fremgangsmate for fremstilling derav NO331655B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19821625A DE19821625C1 (de)	1998-05-15	1998-05-15	Pharmazeutische Zubereitung
PCT/EP1999/003087 WO1999059551A1 (de)	1998-05-15	1999-05-05	Levothyroxin natrium enthaltende pharmazeutische zubereitung

Publications (3)

Publication Number	Publication Date
NO20005758L NO20005758L (no)	2000-11-14
NO20005758D0 NO20005758D0 (no)	2000-11-14
NO331655B1 true NO331655B1 (no)	2012-02-13

Family

ID=7867752

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20005758A NO331655B1 (no)	1998-05-15	2000-11-14	Farmasoytisk preparat i tablettform omfattende levotyroksin-natrium og fremgangsmate for fremstilling derav

Country Status (25)

Country	Link
US (2)	US6646007B1 (ja)
EP (1)	EP1077681B1 (ja)
JP (1)	JP4709379B2 (ja)
CN (1)	CN1145479C (ja)
AR (1)	AR018607A1 (ja)
AT (1)	ATE225651T1 (ja)
AU (1)	AU742382B2 (ja)
BR (1)	BRPI9910445B8 (ja)
CA (1)	CA2333193A1 (ja)
CZ (1)	CZ300908B6 (ja)
DE (2)	DE19821625C1 (ja)
DK (1)	DK1077681T3 (ja)
ES (1)	ES2184452T3 (ja)
HU (1)	HU228958B1 (ja)
ID (1)	ID27281A (ja)
MY (1)	MY120570A (ja)
NO (1)	NO331655B1 (ja)
PL (1)	PL194088B1 (ja)
PT (1)	PT1077681E (ja)
RU (1)	RU2225711C2 (ja)
SK (1)	SK284155B6 (ja)
TW (1)	TW561058B (ja)
UA (1)	UA73474C2 (ja)
WO (1)	WO1999059551A1 (ja)
ZA (1)	ZA200007509B (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6555581B1 (en)	2001-02-15	2003-04-29	Jones Pharma, Inc.	Levothyroxine compositions and methods
US20030224047A1 (en) *	2001-02-15	2003-12-04	Franz G. Andrew	Levothyroxine compositions and methods
ITMI20011401A1 (it) *	2001-07-02	2003-01-02	Altergon Sa	Formulazioni farmaceutiche per ormoni tiroidei
US20030099699A1 (en) *	2001-11-13	2003-05-29	Hanshew Dwight D.	Storage stable thyroxine active drug formulations and methods for their production
US20040152783A1 (en) *	2002-11-05	2004-08-05	Olon Lawrence Peter	Controlled absorption of admixed thyroid hormone formulations
ITMI20110713A1 (it)	2011-04-29	2012-10-30	Bracco Imaging Spa	Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it)	2002-11-13	2004-05-14	Bracco Spa	Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
GB0316206D0 (en) *	2003-07-10	2003-08-13	Glaxo Group Ltd	Pharmaceutical formulation
WO2006054120A1 (en)	2004-11-18	2006-05-26	Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.	Dry powder comprising levothyroxine sodium administered via inhalator
GB0525461D0 (en) *	2005-12-15	2006-01-25	Archimedes Dev Ltd	Pharmaceutical compositions
ITMI20062254A1 (it) *	2006-11-24	2008-05-25	Acraf	Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
WO2014029464A1 (en) *	2012-08-20	2014-02-27	Merck Patent Gmbh	Solid pharmaceutical preparation containing levothyroxine
EP2932963A1 (en)	2014-04-16	2015-10-21	Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.	Stable pharmaceutical dosage forms comprising Levothyroxine sodium
US9682045B2 (en)	2014-11-21	2017-06-20	Cadila Healthcare Limited	Stable pharmaceutical compositions of thyroid hormone drug
WO2018069805A2 (en)	2016-10-10	2018-04-19	Ftf Pharma Private Limited	Method for preparation of liquid oral composition of l-thyroxin
CN109010295A (zh) *	2018-08-29	2018-12-18	北京兴源联合医药科技有限公司	一种左甲状腺素钠冻干口腔崩解片
CN115737576B (zh) *	2022-11-14	2024-05-07	山东创新药物研发有限公司	一种左甲状腺素钠片剂及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR6191M (ja) *	1966-02-18	1968-07-22
US3808332A (en) *	1969-01-27	1974-04-30	Armour Pharma	Pharmaceutical compositions containing the reaction product of a tertiary phosphine with thyroxine
US3621098A (en)	1969-03-17	1971-11-16	Geigy Chem Corp	HYPOTENSIVE METHODS AND COMPOSITIONS UTILIZING HEXAHYDROBENZO{8 b{9 {0 QUINOLIZINES
US3621096A (en) *	1969-04-03	1971-11-16	Univ North Carolina	Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
DE2126533A1 (de) *	1971-05-28	1972-12-14	Merck Patent Gmbh, 6100 Darmstadt	Verfahren zur Herstellung pharma zeutischer Zubereitungen
HUT67319A (en) *	1991-08-30	1995-03-28	Life Medical Sciences Inc	Compositions for treating wounds
US5225204A (en) *	1991-11-05	1993-07-06	Chen Jivn Ren	Stable dosage of levothyroxine sodium and process of production
AU675557B2 (en) *	1993-06-14	1997-02-06	Janssen Pharmaceutica N.V.	Extended release, film-coated tablet of astemizole and pseudoephedrine
GB9325644D0 (en) *	1993-12-15	1994-02-16	Smithkline Beecham Plc	Novel formulation
US5738875A (en) *	1994-10-28	1998-04-14	R.P. Scherer Corporation	Process for preparing solid pharmaceutical dosage forms
SE9500897D0 (sv) *	1995-03-14	1995-03-14	Astra Ab	The pharmacological use of certain cystine derivatives
CN1126589A (zh)	1995-06-09	1996-07-17	中国科学院成都有机化学研究所	一种激素缓释微囊注射剂及其制备方法
DE19541128C2 (de) *	1995-10-27	1997-11-27	Henning Berlin Gmbh & Co	Stabilisierte schilddrüsenhormonhaltige Arzneimittel
WO1997017951A1 (en) *	1995-11-14	1997-05-22	Knoll Pharmaceutical Company	Stabilized thyroid hormone preparations and methods of making same
HUT75956A (en) *	1995-11-29	1997-05-28	Cyclolab	Pharmaceutical composition containing thyroxine
US20010039335A1 (en) *	1997-04-10	2001-11-08	Kenneth Jacobs	Secreted proteins and polynucleotides encoding them
FR2772615B1 (fr) *	1997-12-23	2002-06-14	Lipha	Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
DE19830246A1 (de) *	1998-07-07	2000-01-13	Merck Patent Gmbh	Pharmazeutische Zubereitung

1998
- 1998-05-15 DE DE19821625A patent/DE19821625C1/de not_active Expired - Lifetime
1999
- 1999-05-05 UA UA2000127207A patent/UA73474C2/uk unknown
- 1999-05-05 BR BRPI9910445A patent/BRPI9910445B8/pt not_active IP Right Cessation
- 1999-05-05 WO PCT/EP1999/003087 patent/WO1999059551A1/de active IP Right Grant
- 1999-05-05 DK DK99922182T patent/DK1077681T3/da active
- 1999-05-05 PT PT99922182T patent/PT1077681E/pt unknown
- 1999-05-05 DE DE59903028T patent/DE59903028D1/de not_active Expired - Lifetime
- 1999-05-05 CZ CZ20004201A patent/CZ300908B6/cs not_active IP Right Cessation
- 1999-05-05 ES ES99922182T patent/ES2184452T3/es not_active Expired - Lifetime
- 1999-05-05 AU AU39321/99A patent/AU742382B2/en not_active Expired
- 1999-05-05 SK SK1689-2000A patent/SK284155B6/sk not_active IP Right Cessation
- 1999-05-05 PL PL99346395A patent/PL194088B1/pl unknown
- 1999-05-05 CN CNB998061751A patent/CN1145479C/zh not_active Expired - Lifetime
- 1999-05-05 CA CA002333193A patent/CA2333193A1/en not_active Withdrawn
- 1999-05-05 AT AT99922182T patent/ATE225651T1/de active
- 1999-05-05 EP EP99922182A patent/EP1077681B1/de not_active Expired - Lifetime
- 1999-05-05 HU HU0102125A patent/HU228958B1/hu unknown
- 1999-05-05 ID IDW20002460A patent/ID27281A/id unknown
- 1999-05-05 JP JP2000549216A patent/JP4709379B2/ja not_active Expired - Lifetime
- 1999-05-05 US US09/700,421 patent/US6646007B1/en not_active Expired - Lifetime
- 1999-05-05 RU RU2000131588/15A patent/RU2225711C2/ru active
- 1999-05-12 MY MYPI99001885A patent/MY120570A/en unknown
- 1999-05-14 TW TW088107870A patent/TW561058B/zh not_active IP Right Cessation
- 1999-05-14 AR ARP990102301A patent/AR018607A1/es active IP Right Grant
2000
- 2000-11-14 NO NO20005758A patent/NO331655B1/no not_active IP Right Cessation
- 2000-12-14 ZA ZA200007509A patent/ZA200007509B/en unknown
2003
- 2003-09-15 US US10/661,588 patent/US8008349B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PL194088B1 (pl)	2007-04-30
US8008349B2 (en)	2011-08-30
EP1077681B1 (de)	2002-10-09
BRPI9910445B8 (pt)	2021-05-25
WO1999059551A1 (de)	1999-11-25
BRPI9910445B1 (pt)	2017-05-09
EP1077681A1 (de)	2001-02-28
ATE225651T1 (de)	2002-10-15
HUP0102125A3 (en)	2001-12-28
NO20005758L (no)	2000-11-14
DE59903028D1 (de)	2002-11-14
HUP0102125A2 (hu)	2001-11-28
SK284155B6 (sk)	2004-10-05
DE19821625C1 (de)	2000-01-05
MY120570A (en)	2005-11-30
AR018607A1 (es)	2001-11-28
CN1301148A (zh)	2001-06-27
US6646007B1 (en)	2003-11-11
CA2333193A1 (en)	1999-11-25
AU742382B2 (en)	2002-01-03
CZ300908B6 (cs)	2009-09-09
CZ20004201A3 (cs)	2001-03-14
PL346395A1 (en)	2002-02-11
NO20005758D0 (no)	2000-11-14
AU3932199A (en)	1999-12-06
ZA200007509B (en)	2002-06-14
DK1077681T3 (da)	2002-12-30
PT1077681E (pt)	2003-02-28
RU2225711C2 (ru)	2004-03-20
JP4709379B2 (ja)	2011-06-22
CN1145479C (zh)	2004-04-14
SK16892000A3 (sk)	2001-04-09
BR9910445A (pt)	2001-01-02
UA73474C2 (uk)	2005-08-15
JP2002515421A (ja)	2002-05-28
ES2184452T3 (es)	2003-04-01
ID27281A (id)	2001-03-22
HU228958B1 (en)	2013-07-29
TW561058B (en)	2003-11-11
US20040063611A1 (en)	2004-04-01

Legal Events

Date	Code	Title	Description
2019-06-11	MK1K	Patent expired

Publication	Publication Date	Title
NO331655B1 (no)	2012-02-13	Farmasoytisk preparat i tablettform omfattende levotyroksin-natrium og fremgangsmate for fremstilling derav
US5635209A (en)	1997-06-03	Stabilized composition of levothyroxine sodium medication and method for its production
NZ227032A (en)	1991-05-28	Stabilised ace inhibitors, a process for their preparation and stable pharmaceutical compositions therefrom
EP0274845B1 (en)	1990-09-26	Stable solid pharmaceutical composition containing ibuprofen and codeine
JPH10194969A (ja)	1998-07-28	錠剤組成物
AU751575B2 (en)	2002-08-22	Pharmaceutical levothyroxine preparation
US4670251A (en)	1987-06-02	Microcrystalline tableting excipient derived from whey
US4428951A (en)	1984-01-31	Long acting pharmaceutical composition
EP0563697B1 (en)	2001-07-04	Cytarabine ocfosfate hard capsule
JP2007145733A (ja)	2007-06-14	塩酸サルポグレラート含有錠剤
GB2061111A (en)	1981-05-13	Long acting pharmaceutical composition
JPH11349479A (ja)	1999-12-21	安定なマレイン酸エナラプリル錠剤
JP2002284679A (ja)	2002-10-03	安定な甲状腺ホルモン含有固形製剤組成物
AU2003201879B2 (en)	2007-09-13	Pharmaceutical composition comprising 2,2-Dichloro-12-(4-chlorophenyl)-dodecanoic acid
EP0975337A2 (en)	2000-02-02	Fast release compressed tablet of flurbiprofen
US5281421A (en)	1994-01-25	Gemfibrozil formulations
MXPA00011182A (en)	2001-09-07	Pharmaceutical preparation containing levothyroxine sodium
JP2716619B2 (ja)	1998-02-18	塩酸ミドドリン含有製剤
JP2002226371A (ja)	2002-08-14	プラバスタチンナトリウムの錠剤
MXPA00012906A (en)	2001-09-07	Pharmaceutical levothyroxine preparation